Home Cart Sign in  
Chemical Structure| 29342-05-0 Chemical Structure| 29342-05-0

Structure of Ciclopirox
CAS No.: 29342-05-0

Chemical Structure| 29342-05-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Ciclopirox inhibits iron-dependent enzymes PHD2 (pIC50 = 5.8) and deoxyhypusine hydroxylase. It is an antifungal and iron-chelating agent.

Synonyms: HOE296b; Penlac

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Ciclopirox

CAS No. :29342-05-0
Formula : C12H17NO2
M.W : 207.27
SMILES Code : O=C1C=C(C)C=C(C2CCCCC2)N1O
Synonyms :
HOE296b; Penlac
MDL No. :MFCD00599441
InChI Key :SCKYRAXSEDYPSA-UHFFFAOYSA-N
Pubchem ID :2749

Safety of Ciclopirox

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Related Pathways of Ciclopirox

epigenetics

Isoform Comparison

Biological Activity

Target
  • ATPase

In Vitro:

Cell Line
Concentration Treated Time Description References
SK-N-SH 5 µM 4 days Inhibited neuroblastoma cell proliferation and survival PMC5581701
IMR-32 5 µM 4 days Inhibited neuroblastoma cell proliferation and survival PMC5581701
SK-N-AS 5 µM 4 days Inhibited neuroblastoma cell proliferation and survival PMC5581701
Calu-3 2.8 μmol/L 24 hours To evaluate the inhibitory effect of Ciclopirox on SARS-CoV-2 replication, results showed that Ciclopirox significantly inhibited viral RNA levels. PMC11143514
HeLa-ACE2 1.7 μmol/L 24 hours To evaluate the inhibitory effect of Ciclopirox on SARS-CoV-2 replication, results showed that Ciclopirox significantly inhibited viral RNA levels. PMC11143514
Vero-E6 1.3 μmol/L 24 hours To evaluate the inhibitory effect of Ciclopirox on SARS-CoV-2 replication, results showed that Ciclopirox significantly inhibited viral RNA levels. PMC11143514
HEK293T 5-10 μmol/L 48 hours To screen small-molecule compounds that promote NP degradation, results showed that Ciclopirox significantly reduced NP expression. PMC11143514
HepG2.2.15 cells 1μM 3 days Screening compounds for HBV replication inhibition, finding that Ciclopirox significantly inhibits HBV DNA secretion. PMC6522524
BE(2)-C 5 µM 4 days Inhibited neuroblastoma cell proliferation and survival, induced cell morphology changes such as neurite outgrowth PMC5581701
PANC1 cells 5 μM 72 hours To evaluate the effect of Azeliragon on the proliferation of Panc1 cells, results showed that Azeliragon inhibited cell proliferation in a dose-dependent manner PMC4233190
FG cells 5 μM 72 hours Inhibited cell proliferation and eIF5A1 hypusination PMC4233190
SiHa cells 20 μM 24 hours To evaluate the inhibitory effect of CPX on the proliferation of cervical cancer cells. Results showed that CPX treatment significantly inhibited the proliferation of SiHa cells. PMC9144037
HeLa cells 20 μM 24 hours To evaluate the ability of BSA–RuII(CO)2 complex to release CO in HeLa cells, results showed a significant increase in intracellular fluorescence indicating CO release. PMC9144037
SW480 20 μM 24 hours LPCAT2 knockdown promoted CRC cell proliferation PMC6735393
HCT116 20 μM 24 hours PMC6735393
NB-1691 5 µM 4 days Inhibited neuroblastoma cell proliferation and survival PMC5581701
Huh-7 cells 1μM 36 hours PMC6522524
HS68 5 µM 4 days PMC5581701

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
BALB/C mice SARS-CoV-2 infection model Intraperitoneal injection 20 mg/kg/day Once daily for 5 days To evaluate the inhibitory effect of Ciclopirox on SARS-CoV-2 replication in vivo, results showed that Ciclopirox significantly reduced viral titers and lung pathology. PMC11143514
SD rats Middle cerebral artery occlusion (MCAO) model Intravenous injection 3 mg/kg Single or multiple doses, lasting for 7 days Evaluate the alleviating effect of CPX on brain infarction, neurological deficits and brain edema PMC7049605
PXB mice (humanized liver mouse model) HBV infection model Oral 5 mg/kg Once daily for 5 weeks Evaluating the inhibitory effect of Ciclopirox on HBV replication in vivo, finding it significantly reduces serum HBV DNA levels. PMC6522524
SCID mice Neuroblastoma disseminated disease model Subcutaneous pump continuous release 12 mg/ml Continuous for 4 weeks CPX significantly reduced tumor burden and inhibited or prevented disease dissemination PMC5581701
Nude mice HCT116 xenograft model Oral gavage 25 mg/kg Once daily for three weeks To evaluate the antitumor effect of CPX in vivo, results showed that CPX significantly inhibited tumor growth. PMC6735393
C57BL/6 mice MOC2-E6/E7 subcutaneous xenograft model Intraperitoneal injection 10 mg/kg and 15 mg/kg Once or twice daily for 21 days To evaluate the inhibitory effect of Ciclopirox on tumor growth in vivo. The results showed that SC144 significantly delayed tumor growth, while the effect of CPX was not significant. PMC7295058

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00382330 Vulvar Cancer WITHDRAWN - University of Medicine and Den... More >>tistry of NJ, Newark, New Jersey, 07107, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

4.82mL

0.96mL

0.48mL

24.12mL

4.82mL

2.41mL

48.25mL

9.65mL

4.82mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories